The following tables of frequently used oncology drugs are intended to assist practice managers, other healthcare providers, and payers in the proper use of coding and billing information associated with the treatment of their patients. For the latest and most detailed pricing (including all package sizes), please go to BuyandBill.com or PriceDoctoRx.com.
Please click on an oncology drug's brand name to view additional information on BuyandBill.com.
-
TABLE 1Office-Administered Oncology Drugs and Corresponding Codes and Pricing
ASP+6% per unit, lowest WAC per unit, and lowest AWP per unit values are up to date as of 10/1/2021.
-
paclitaxel albumin-stabilized nanoparticle formulationCelgene CorporationJ9264$14.08$15.12$18.141/1/2021tocilizumabGenentechJ3262$5.55$5.76$6.921/1/2020brentuximab vedotinSeattle GeneticsJ9042$189.34$185.50$222.606/30/2021netupitant and palonosetron hydrochlorideHelsinn Therapeutics (US)J1454$571.22$683.18$819.827/1/2021pemetrexed disodiumEli Lilly and CompanyJ9305$74.93$76.97$92.367/1/2021copanlisib hydrochlorideBayerJ9057N/A$79.30$95.161/1/2021darbepoetin alfaAmgen USAJ0881$3.15$7.74$9.291/17/2017ofatumumabNovartis Pharmaceuticals CorporationJ9302$63.96$60.34$72.401/3/2020bevacizumabGenentechJ9035$70.41$79.69$95.636/3/2019avelumabEMD SeronoJ9023$86.19$85.13$102.167/1/2021bendamustine hydrochlorideTevaJ9034$19.65$24.74$29.693/23/2018inotuzumab ozogamicinPfizer (Wyeth)J9229$2,371.62$2,270.94$2,725.117/1/2021belantamab mafodotin-blmfGlaxoSmithKlineJ9037$42.78$42.01$50.417/1/2021blinatumomabAmgen USAJ9039$123.88$121.20$145.441/22/2021lisocabtagene maraleucelBristol-Myers Squibb CompanyQ2054$422,609.00b$410,300.00$492,360.002/5/2021
-
irinotecan hydrochlorideMulti-source, genericaJ9206$2.35$3.60$4.325/6/2019trilaciclibG1 TherapueticsJ1448$4.97$4.72$5.672/22/2021ramucirumabEli Lilly and CompanyJ9308$62.69$62.81$75.387/1/2021daratumumabJanssen BiotechJ9145$57.55$58.24$69.881/15/2021daratumumab and hyaluronidase-fihjJanssen BiotechJ9144$45.10$44.10$52.921/15/2021rasburicaseSanofi-AventisJ2783$315.06$319.34$383.217/1/2021epirubicin hydrochlorideMulti-source, genericaJ9178$1.69$1.85$2.221/1/2021elotuzumabBristol-Myers Squibb CompanyJ9176$6.77$6.67$8.007/1/2021fam-trastuzumab deruxtecan-nxkiDaiichi SankyoJ9358$24.27$23.65$28.387/1/2021epoetin alfaAmgen USAJ0885$8.15$16.58$19.901/17/2017cetuximabEli Lilly and CompanyJ9055$66.71$69.34$83.217/1/2021asparaginase Erwinia chrysanthemiJazz PharmaceuticalsJ9019$427.27$403.08$483.706/28/2021fulvestrantAstraZenecaJ9395$15.98$96.95$116.341/1/2019pegfilgrastimMylan Institutional LLCQ5108$211.19$347.92$417.507/9/2018
-
obinutuzumabGenentechJ9301$64.54$68.49$82.191/1/2021gemcitabine hydrochlorideMulti-source, genericaJ9201$3.82$7.70$9.242/19/2019filgrastimTeva (Cephalon)J1447$0.46$0.83$1.009/4/2018eribulin mesylateGenentechJ9355$89.81$103.89$124.676/3/2019trastuzumab and hyaluronidase-oyskGenentechJ9356$71.85$77.92$93.504/8/2019topotecan hydrochlorideMulti-source, genericaJ9351$0.77$2.67$3.215/14/2013idarubicin hydrochlorideMulti-source, genericaJ9211$34.75$30.00$36.004/26/2018durvalumabAstraZenecaJ9173$76.86$74.40$89.287/1/2020talimogene laherparepvecAmgen USAJ9325$57.26$54.86$65.831/22/2021gemcitabine hydrochlorideSun Pharmaceutical IndustriesJ9198$34.00$38.00$45.604/8/2019recombinant interferon alfa-2bMerck Sharp & Dohme CorpJ9214$33.24$30.73$36.881/5/2018romidepsinMulti-source, genericaJ9315N/A$319.87$383.8410/6/2017
-
cabazitaxelSanofi-AventisJ9043$189.00$202.09$242.517/1/2021ado-trastuzumab emtansineGenentechJ9354$34.18$32.96$39.561/1/2021pembrolizumabMerck Sharp & Dohme Corp.J9271$52.75$51.34$61.619/30/2021tisagenlecleucelNovartis Pharmaceuticals CorporationQ2042$434,337.60b$373,000.00$447,600.005/1/2018carfilzomibAmgen USAJ9047$41.10$42.99$51.581/22/2021cemiplimab-rwlcRegeneron PharmaceuticalsJ9119$27.54$26.92$32.308/6/2021moxetumomab pasudotox-tdfkAstraZeneca (Innate Pharma)J9313$23.39$22.07$26.4810/1/2020tafasitamab-cxixMorphosys USJ9349$12.62$12.18$14.627/1/2021bevacizumabAmgen USAQ5107$44.56$69.77$83.738/18/2021gemtuzumab ozogamicinPfizer (Wyeth)J9203$207.99$199.16$239.007/1/2021
-
paclitaxel albumin-stabilized nanoparticle formulationMulti-source, genericaJ9267$0.13$0.11$0.198/7/2014pegfilgrastimAmgen USAJ2505$2,221.63$6,417.99$7,701.568/8/2021filgrastimAmgen USAJ1442$0.97$1.04$1.2510/19/2017romiplostimAmgen USAJ2796$83.47$82.59$99.101/22/2021pegfilgrastimPfizerQ5122$284.69$130.83$157.0011/30/2020irinotecan hydrochloride liposomeIpsen BiopharmaceuticalsJ9205$57.20$57.49$68.991/12/2021nivolumabBristol-Myers Squibb CompanyJ9299$28.86$28.25$33.908/31/2021enfortumab vedotin-ejfvSeattle GeneticsJ9177$30.17$29.56$35.489/30/2021pertuzumabGenentechJ9306$13.56$13.17$15.801/1/2021pertuzumab, trastuzumab, and hyaluronidase-zzxfGenentechJ9316$72.15$70.59$84.717/6/2020polatuzumab vedotin-piiqGenentechJ9309$113.57$107.14$128.579/28/2020necitumumabEli Lilly and CompanyJ9295$5.74$5.41$6.4912/28/2018epoetin alfaJanssen ProductsJ0885$8.15$26.73$32.071/10/2019denosumabAmgen USAJ0897$21.19$22.57$27.801/22/2021
-
epoetin alfaPfizerQ5105$0.87$1.10$1.3211/9/2020rituximabGenentechJ9312$86.94$93.95$112.746/3/2019rituximab and hyaluronidase humanGenentechJ9311$37.94$46.98$56.377/1/2018docetaxelMulti-source, genericaJ9171$0.48$1.06$1.272/14/2018atezolizumabGenentechJ9022$79.75$78.92$94.701/1/2021bendamustine hydrochlorideTevaJ9033$22.01$29.72$35.661/1/2018rituximabTeva (Cephalon)Q5115$60.58$84.55$101.4711/9/2019pegfilgrastimCoherus BiosciencesQ5111$222.38$347.92$417.501/3/2019bortezomibMillennium PharmaceuticalsJ9041$45.16$45.80$54.967/1/2016azacitidineCelgeneJ9025$0.93$1.00$1.209/8/2020denosumabAmgen USAJ0897$21.19$20.76$24.911/22/2021pegfilgrastimSandozQ5120$245.43$327.13$392.5511/7/2019bevacizumab-bvzrPfizerQ5118$52.37$61.34$73.6112/31/2019zoledronic acidNovartis Pharmaceuticals CorporationJ3489$8.25$11.00$13.2010/12/2020
aProviders should check with their vendors for the lowest available pricing on multi-source products.bAPC rate.APC indicates ambulatory payment classification; ASP, average sales price; AWP, average wholesale price; HCPCS, Healthcare Common Procedure Coding System; N/A, not available; WAC, wholesale acquisition cost. -
-
TABLE 2Self-Administered Oncology Drugs and Corresponding Pricing
-
everolimusNovartis Pharmaceuticals Corporation$536.30$643.561/15/2019alectinibGenentech$66.07$79.291/1/2021brigatinibTakeda$189.17$227.001/4/2021exemestanePfizer (Pharmacia and Upjohn)$36.90$44.281/1/2021avapritinibBlueprint Medicines$1,118.93$1,342.726/16/2021erdafitinibJanssen$295.69$354.831/15/2021bosutinibPfizer$137.14$164.571/1/2021encorafenibArray Biopharma$70.43$84.511/1/2021zanubrutinibBeiGene USA$112.43$134.912/1/2021
-
cabozantinib-s-malateExelixis$722.09$866.511/1/2021acalabrutinibAstraZeneca$234.40$281.2810/31/2017cabozantinib-s-malateExelixis$160.71$192.851/1/2020duvelisibSecura Bio$267.23$320.674/26/2021cobimetinib fumarateGenentech$111.19$133.431/1/2018glasdegib maleatePfizer$311.00$373.201/1/2021aprepitantMerck Sharp & Dohme Corp.$218.77$262.531/5/2018vismodegibGenentech$420.20$504.251/1/2021apalutamideJanssen$106.94$128.331/15/2021
-
afatinib dimaleateBoehringer$336.08$403.301/1/2021imatinib mesylateNovartis$93.64$112.377/7/2015palbociclibPfizer$622.47$746.961/1/2021ponatinib hydrochlorideAriad Pharma$552.03$662.4410/1/2016enasidenib mesylateCelgene$941.53$1,129.841/1/2021ibrutinibPharmacyclics$165.78$198.941/1/2021axitinibPfizer$92.38$110.861/1/2021decitabine and cedazuridineTaiho$1,499.00$1,798.808/17/2020fedratinib hydrochlorideCelgene$182.88$219.451/1/2021gefitinibAstraZeneca$259.63$311.554/1/2019
-
ruxolitinib phosphateIncyte Corporation$252.05$302.4610/7/2021ribociclibNovartis$224.93$269.911/6/2021lenvatinib mesylateEisai$226.25$271.517/13/2021trifluridine and tipiracil hydrochlorideTaiho Oncology$179.22$215.071/12/2021lorlatinibPfizer$196.68$236.021/1/2021sotorasibAmgen$74.58$89.505/28/2021olaparibAstraZeneca$120.41$144.497/1/2020trametinib dimethyl sulfoxideNovartis$123.41$148.091/6/2021binimetinibArray Biopharma$69.10$82.911/1/2021
-
neratinib maleatePuma Biotech$102.07$122.488/1/2021sorafenib tosylateBayer$173.00$207.601/1/2021ixazomib citrateTakeda$3,631.33$4,357.601/4/2021darolutamideBayer$99.14$118.971/1/2021sonidegibSun Pharma$415.40$498.484/1/2021azacitidineCelgene$1,511.29$1,813.553/8/2021pemigatinibIncyte Corporation$1,214.29$1,457.144/20/2020alpelisibNovartis$624.90$749.881/6/2021alpelisibNovartis$312.45$374.941/6/2021pomalidomideCelgene$907.61$1,089.131/1/2021eltrombopag olamineNovartis$188.01$225.611/6/2021
-
lenalidomideCelgene$797.34$956.811/1/2021entrectinibGenentech$192.27$230.721/1/2021rucaparib camsylateClovis Oncology$144.75$173.704/1/2021dasatinibBristol-Myers Squibb Company$140.20$168.241/1/2021sunitinib malatePfizer$202.09$242.511/1/2021abemaciclibLilly$233.18$279.811/12/2021crizotinibPfizer$309.78$371.731/1/2021capecitabineGenentech$13.56$16.271/1/2017selinexorKaryopharm Therapeutics$721.19$865.434/1/2021vorinostatMerck Sharp & Dohme Corp.$125.08$150.101/5/2018
AWP indicates average wholesale price; NDC, National Drug Code; WAC, wholesale acquisition cost. -
This information was supplied by: